Cathy E. Minehan, former board chair of Massachusetts General Hospital (MGH) and former president of the Federal Reserve Bank, Valerie Mosley, CFA, founder of BrightUp and former partner at Wellington Management Company, and Chandra Ramanathan, PhD, MBA, executive-in-residence at Mass General Brigham (MGB) and former global head of Pharma R&D Open Innovation at Bayer, have joined McLean Hospital’s Board of Trustees.
“We are delighted to have Cathy, Valerie, and Chandra join as McLean trustees. All three are eminent leaders and innovators in their respective fields—finance, business, global health, translational research, and technology. Their guidance, support, and oversight as board members will be enormously valuable to advancing McLean’s mission,” said Scott L. Rauch, MD, McLean’s president and psychiatrist in chief.
McLean Board Chair Carol Vallone added, “Cathy’s and Valerie’s experience in business best practices and corporate social responsibility, and Chandra’s expertise in translating scientific ideas into treatments and access for patients, are tremendous assets to our board and will benefit the entire McLean community. We are thrilled to have them joining us.”
Cathy E. Minehan
Minehan is a director of Bright Horizons Family Solutions LLC, and a trustee of The MITRE Corporation and the Brookings Institution. She is an honorary trustee of MGH, after serving for more than 10 years as board chair, and is co-chair of the Mass General Brigham Institutional Conflict Committee.
She is also the outside board member of the American Board of Thoracic Surgeons, and serves on numerous other boards, as well as on the Massachusetts Business Roundtable and the Boston Women’s Workforce Council, which works to end the gender wage gap in Boston.
“I knew about the excellence of McLean from many sources, but it was not until I needed to find help for my husband who was quite ill with Alzheimer’s that I realized the magic of the place—its truly amazing care and caregivers,” said Minehan.
“They helped me as well as him, and I will never forget their excellence and kindness. What better reason to join the McLean board than to help ensure that level of care remains both the standard and available to all?”
Minehan was the first woman to serve as president of the Federal Reserve Bank of Boston. After retiring from her 39-year career with the Federal Reserve System, she served as dean of Simmons College’s School of Management. She is a graduate of the University of Rochester and a member of its Board of Trustees. She holds an MBA from New York University.
Valerie Mosley, CFA
Mosley founded BrightUp, a financial wellness platform that democratizes the creation of personal and financial wealth, in 2020. Previously, she spent 20 years at Wellington Management Company, LLP, and retired as a partner and senior vice president portfolio manager and investment strategist. She serves on several corporate boards, as well as on the board of a social venture capital firm.
Mosley cited McLean’s strong performance in mental health treatment, education, and research, as well as the hospital’s commitment to pursuing a variety of leading-edge capabilities for broader societal good, in her decision to join the board.
“McLean is a leading psychiatric hospital and as an investor, I’m eager to invest in quality assets that I know will add value,” Mosley said. “In addition, I’m passionate about positively impacting our society. McLean does a fantastic job serving individuals and families. I’m particularly excited about and interested in using technology to ensure more people have access to critically important mental health services.”
Mosley has been recognized as The International Person of the Year by The UK’s Power List, one of the 50 Most Powerful Women in Business, and one of the Top 75 African Americans on Wall Street by Black Enterprise Magazine. She earned a bachelor’s degree from Duke University and an MBA in finance from the Wharton School of Business.
Chandra Ramanathan, PhD, MBA
In his position as executive-in-residence at MGB, Ramanathan works with investigators to identify and advance technologies toward commercialization. He also advises start-ups in the therapeutics and cell and gene therapy technology space.
He said he is excited to join the McLean board because of the great potential clinical innovation holds for addressing unmet mental health needs.
“There is tremendous opportunity to couple the advances in our understanding of the complexity of the brain with digital tools, which can lead to transformative options in neuropsychiatry and patient care,” he said.
Ramanathan has led several initiatives across pharma, biotech, start-ups, and academia from early-stage discovery programs to launching new products.
Prior to joining MGB, Ramanathan held various leadership positions at Bayer. Most recently, he was the global head of Pharma R&D Open Innovation, where he led open innovation centers (OICs) around the world. The OICs focus on early access to breakthrough technologies, management of strategic alliances, and public-private partnerships.
Ramanathan is an adjunct assistant professor at the Tufts School of Medicine and is on the Board of Directors of MassBIO, the Massachusetts Biotech Council. He is also a member of the Innovation, Development & Entrepreneurial Advisory Board at Johns Hopkins University.
Ramanathan earned an MBA from Columbia Business School, a PhD in genomics/bioinformatics from the University of Georgia, an MS in medicinal chemistry from the Indian Institute of Technology (Banaras Hindu University), and a BS in pharmacy from Birla Institute of Technology and Science.
Ramanathan, Mosely, and Minehan begin their roles as three long-time board members—W. Lloyd “Skip” Snyder, Rick Kelleher, and Bob Pierce—stepped aside this year after serving the hospital for 12 years each, the maximum tenure allowed. Snyder, Kelleher, and Pierce each will continue to stay involved as honorary trustees.
Journalist or member of the media? We are available 24/7 for media requests.